POT-4 is a complement inhibitor, which shuts down the complement activation cascade that could otherwise lead to local inflammation, tissue damage and upregulation of angiogenic factors such as
ResponseDX: Colon and ResponseDX: Lung are proprietary PCR-based tests in a panel, which include the analysis of KRAS mutation and serve to help physicians with therapeutic treatment decisions
The FDA export license clears the way to provide patients in Russia with Oncophage, which will continue to be manufactured at the company’s facility in Lexington, Massachusetts. The
The trial is expected to begin enrollment in the fourth quarter of 2008 at three sites in Israel, and is designed to enroll a total of 30 patients
Mr Patriacca, currently an independent financial consultant, most recently served as vice president, CFO and Treasurer of MacroChem, a US-based publicly-traded specialty pharmaceutical company. Mr Patriacca has received
In less than one hour, Xpert MRSA/SA skin and soft tissue infections test processes specimens from suspected skin and soft tissue infection swabs to determine if a patient
The round was supported by an international syndicate of investors, led by Aravis Venture, a Swiss venture capital firm. Proquest Investments, a first tier US venture capital co-invested
The company has also introduced changes to its website, which presents current information about Limerick BioPharma and provides an overview of its proprietary efflux pump activators. Limerick has
The spin-off of the clinical and medical products businesses will create a new, global company headquartered in San Diego, with offerings for infusion, medication and supply dispensing, respiratory
These new patents relate to the company’s focus on the development of rapid and easy to use clinical diagnostic products. The first newly issued patent has broad applicability
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.